Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | SPR | P35270 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22790988 | 1.00 | KDM4E (0.64) | KDM4EMAPK1HIF1APAOXFAAH | |
| SCHEMBL22525935 | 1.00 | KDM4E (0.64) | KDM4EMAPK1HIF1APAOXFAAH | |
| SCHEMBL23568563 | 0.98 | KDM4E (0.60) | KDM4EMAPK1HIF1APAOXFAAH | |
| SCHEMBL22849696 | 0.94 | KDM4E (0.54) | KDM4EMAPK1HIF1APAOXFAAH | |
| SCHEMBL7786356 | 0.92 | FAAH (0.55) | KDM4EMAPK1HIF1APAOXFAAH | |
| SCHEMBL8537389 | 0.92 | FAAH (0.55) | KDM4EMAPK1HIF1APAOXFAAH | |
| SCHEMBL23568089 | 0.91 | KDM4E (0.53) | KDM4EMAPK1HIF1APAOXFAAH | |
| SCHEMBL24508451 | 0.90 | KDM4E (0.52) | KDM4EMAPK1HIF1APAOXFAAH | |
| SCHEMBL25830725 | 0.90 | KDM4E (0.52) | KDM4EMAPK1HIF1APAOXFAAH | |
| SCHEMBL18098230 | 0.90 | KDM4E (0.46) | KDM4EMAPK1HIF1APAOXFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2022140472-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2021231778-A1 | CORONAVIRUS PROTEASE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | KDM4E 935/4885MAPK1 3746/4885HIF1A 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.